AJP - Endocrinology and Metabolism, Vol 253, Issue 5 E508-E514, Copyright © 1987 by American Physiological Society

ARTICLES

Periodic interactions of GH-releasing factor and somatostatin can augment GH release in vitro

J. Weiss, M. J. Cronin and M. O. Thorner
Department of Physiology, University of Virginia School of Medicine, Charlottesville 22908.

Growth hormone (GH) is secreted as pulses in vivo. To understand the signals governing this periodicity, we have established a perifusion-based model of pulsatile GH release. Male rat anterior pituitaries were dispersed and perifused with pulses of human growth hormone-releasing factor-(1--40) (GHRF), with or without a continuous or discontinuous somatostatin tonus. An experiment was composed of a 1-h base-line collection followed by four 3-h cycles; each contained single or paired 10-min infusion(s) of 3 nM GHRF. In testing the impact of somatostatin, the protocol was identical except that 0.3 nM somatostatin was added 30 min into the base-line period and then was either continued throughout the study or withdrawn during the periods of GHRF infusion. GH base lines with somatostatin were lower than vehicle base lines (P less than 0.05). GHRF pulses generated consistent peaks of GH release between 200 and 300 ng. min-1. (10(7) cells)-1, and these peaks were not altered by continuous somatostatin. In contrast, withdrawal of somatostatin during GHRF administration elicited markedly higher GH peaks (P less than 0.05) and more total GH release (P less than 0.05). This response could not be accounted for by the additive effects of GHRF and somatostatin withdrawal.

This article has been cited by other articles:

				L. Beranek, I. Hajdu, J. Gardi, P. Taishi, F. Obal Jr., and J. M. Krueger Central administration of the somatostatin analog octreotide induces captopril-insensitive sleep responses Am J Physiol Regulatory Integrative Comp Physiol, November 1, 1999; 277(5): R1297 - R1304. [Abstract] [Full Text] [PDF]